Qingmei Hong - Concepedia

Author

Qingmei Hong

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

H. A. Parkes, Hong, Qingmei, Q. HONG, Qingmei Hong

Publications

487

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military Academy

About

Qingmei Hong is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	286
2	Biochemistry	12	13	273
3	Natural Sciences	7	7	121
4	Engineering	6	6	131
5	Health Sciences	3	3	72

Qingmei Hong

Publications

381

Citations

H-Index

Page 1

	Year	Citations
Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain Harry R. Chobanian, Yan Guo, Ping Liu, ACS Medicinal Chemistry Letters Pain MedicineHigh ThroughputNeuropathic PainMolecular PainPharmacotherapy	2014	41
Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase Ping Liu, Terence G. Hamill, Marc Chioda, ACS Medicinal Chemistry Letters EngineeringImaging AgentPet-mriNeurochemical BiomarkersPositron Emission Tomography	2013	36
Preparations of Secondary Amines and .beta.-Amino Esters via Additions of Grignard and Reformatsky Reagents to Imines and by One-Pot Reactions of Primary Amines, Aldehydes, and Grignards Alan R. Katritzky, Qingmei Hong, Zhijun Yang The Journal of Organic Chemistry Combinatorial ChemistryEnantioselective SynthesisEngineeringBiochemistryAltmetric Attention Score	1995	29
1-(Trimethylsilyl)benzotriazole-Assisted Addition of Grignard Reagents to Imines: A Versatile Approach to Aliphatic Secondary Amines Alan R. Katritzky, Qingmei Hong, Zhijun Yang The Journal of Organic Chemistry Benzotriazole-assisted AdditionCombinatorial ChemistryMolecular SciencesEngineeringGrignard Reagents	1994	27
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety Shuwen He, Qingmei Hong, Zhong Lai, ACS Medicinal Chemistry Letters PharmacotherapyChemical BiologyPharmaceutical ChemistryPre-clinical PharmacologyTranslational Pharmacology	2014	26
Discovery of MK-1421, a Potent, Selective sstr3 Antagonist, as a Development Candidate for Type 2 Diabetes Shrenik K. Shah, Shuwen He, Liangqin Guo, ACS Medicinal Chemistry Letters Development CandidateCardiovascular PharmacologyPharmacotherapyExperimental PharmacologyTranslational Pharmacology	2015	23
Discovery of a spiroindane based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor agonist Shuwen He, Zhixiong Ye, Peter H. Dobbelaar, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistryBiochemistryFunctional SelectivityMedicineNatural Sciences	2010	23
Discovery of highly potent and efficacious MC4R agonists with spiroindane N-Me-1,2,4-triazole privileged structures for the treatment of obesity Shuwen He, Zhixiong Ye, Peter H. Dobbelaar, Bioorganic & Medicinal Chemistry Letters BiochemistryFunctional SelectivitySpiroindane N-me-1,2,4-triazoleMedicineRational Drug Design	2010	20
The Discovery of MK-4256, a Potent SSTR3 Antagonist as a Potential Treatment of Type 2 Diabetes Shuwen He, Zhixiong Ye, Quang Truong, ACS Medicinal Chemistry Letters PharmacotherapyExperimental PharmacologyMolecular PharmacologyMetabolic SyndromeStructure-activity Relationship Study	2012	18
Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands Raman K. Bakshi, Qingmei Hong, Rui Tang, Bioorganic & Medicinal Chemistry Letters Medicinal ChemistrySignal TransductionPrivileged StructureG Protein-coupled ReceptorMedicine	2005	18

Page 1